Chase Coleman's NVO Position Overview
Chase Coleman (via Tiger Global Management LLC) currently holds 0 shares of Novo Nordisk A/S (NVO) worth $0, representing 0.00% of the portfolio. First purchased in 2023-Q2, this medium-term investment has been held for 10 quarters.
Based on 13F filings, Chase Coleman has maintained a strategic position in NVO, demonstrating sustained confidence in this investment. Largest reduction occurred in Q3 2025, reducing 1.27 M shares.
Analysis based on 13F filings available since 2013 Q2
Chase Coleman's Novo Nordisk A/S (NVO) Holding Value Over Time
Track share changes against reported price movement
Quarterly Novo Nordisk A/S (NVO) Trades by Chase Coleman
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2023 | +1.27 M | New Buy | 1.27 M | $80.92 |
| Q3 2025 | -1.27 M | Sold Out | 0 | $0.00 |
Chase Coleman's Novo Nordisk A/S Investment FAQs
Chase Coleman first purchased Novo Nordisk A/S (NVO) in Q2 2023, acquiring 1,269,000 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Chase Coleman has held Novo Nordisk A/S (NVO) for 10 quarters since Q2 2023.
Chase Coleman's largest addition to Novo Nordisk A/S (NVO) was in Q2 2023, adding 1,269,000 shares worth $102.68 M.
According to the latest 13F filing for Q3 2025, Chase Coleman's firm, Tiger Global Management LLC, owns 0 shares of Novo Nordisk A/S (NVO), valued at approximately $0.
As of the Q3 2025 filing, Novo Nordisk A/S (NVO) represents approximately 0.00% of Chase Coleman's publicly disclosed stock portfolio, making it one of their key holdings.
Chase Coleman's peak holding in Novo Nordisk A/S (NVO) was 1,269,000 shares, as reported at the end of Q2 2023.